The lower contribution of the perforin pathway (over the IFN-γ pathway) to tumor killing by CAR4 T cells was also reflected by the fact Prf1−/− CAR4 T cells displayed similar therapeutic benefit as compared to WT CAR4 T cells (Fig. 3f). The gene discussed is PRF1; the disease is neoplasm.